[Immunological and pathogenetic aspects of imunofan administration in aged patients with duodenal ulcer].

Abstract

AIM:

To specify immunological and pathogenetic aspects of imunophan use in aged patients with duodenal ulcer (DU).

MATERIAL AND METHODS:

Imunophan was given to 24 DU patients (mean age 62.0 +/- 1.5 years), in whom the size of ulcer varied from 0.6 to 2.1 cm.

RESULTS:

The patients on anti-ulcer therapy plus imunophan had a pain relief median 6.2 +/- 0.2 days (p < 0.001), control ones--11.8 +/- 0.1 days. The median of scarring duration in the test group was 16.2 +/- 0.2 days (p < 0.001), in the controls--23.8 +/- 0.3 days. In 3 (30.0%) cases the scars were rough. The count of T-lymphocytes in the study group increased from 53.1 +/- 0.6 to 65.1 +/- 0.2% (p < 0.001), of T-helpers/inductors--from 27.8 +/- 0.2 to 38.5 +/- 0.3% (p < 0.001), of cytotoxic T-lymphocytes--from 18.5 +/- 0.5 to 27.3 +/- 0.3 (p < 0.001), of B-lymphocytes--from 12.3 +/- 0.2 to 19.1 +/- 0.1% (p < 0.001). The therapy including imunophan reduced concentration of malonic dialdehide by 23.5%, trienic conjugates by 61.6%; raised the level of superoxide dismutase 1.6-fold, catalase 1.4-fold, glutathione reductase by 41.9% (p < 0.001). Neither immune status nor LPO-AOD changed significantly in patients on the basic therapy alone.

CONCLUSION:

The results obtained evidence for a positive action of imunophan on inflammation, immune status and antioxidant defense. Therefore, imunophan can be recommended as an adjuvant of basic anti-ulcer therapy in elderly and senile patients.

• Authors: I V Butorov, Iu P Osoianu, S I Butorov, V V Maksimov
• Journal: Terapevticheskii arkhiv (Ter Arkh) Vol. 79 Issue 2 Pg. 18-22 ( 2007) ISSN: 0040-3660 [Print] Russia (Federation)
• PMID: 17460962 (Publication Type: Clinical Trial, English Abstract, Journal Article)

Chemical References

• Adjuvants, Immunologic
• Immunoglobulin A
• Oligopeptides
• thymohexin
• Malondialdehyde
• Superoxide Dismutase

Topics

• Adjuvants, Immunologic (administration & dosage, pharmacology, therapeutic use)
• Disease Progression
• Duodenal Ulcer (drug therapy, immunology, physiopathology)
• Female
• Humans
• Immunoglobulin A (drug effects, immunology)
• Leukocytes (metabolism)
• Male
• Malondialdehyde (antagonists & inhibitors)
• Middle Aged
• Oligopeptides (administration & dosage, pharmacology, therapeutic use)
• Superoxide Dismutase (antagonists & inhibitors)